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By 2000, more than 1 202 000 percutaneous and 519 000surgical revascularization procedures were being per-
formed annually in the United States.1 The 3 potential reasons
to recommend myocardial revascularization are (1) to allevi-
ate symptoms of myocardial ischemia, (2) to reduce the risks
of future mortality, and (3) to treat or prevent morbidities
such as myocardial infarction, arrhythmias, or heart failure.
To minimize biases, this article focuses on data from pro-
spective, randomized, controlled trials (RCTs) comparing
coronary artery bypass graft (CABG) surgery, percutaneous
transluminal coronary angioplasty (PTCA), stents, and med-
ical therapy for chronic coronary artery disease (CAD). The
data are interpreted in the context of a conceptual framework
based on patient risk, methodological characteristics of the
evidence, and the occurrence of clinically relevant end points.
CABG Surgery Versus Medical Therapy
Mortality
Of 7 RCTs conducted 2 decades ago, only 1 found a
statistically significant difference in mortality between the
medical and surgical groups. A trend toward lower mortality
was noted in other trials.
Meta-analysis of all 7 trials,2 totaling 2649 patients, dem-
onstrated a reduction in mortality after CABG surgery, but
this was not apparent for the first 3 years of follow-up (Figure
1). Thereafter, risk reductions were significant at 5, 7, and 10
years (relative risk [RR]0.61, 0.68, and 0.83, respectively),
although 40% of patients initially assigned to medical treat-
ment subsequently underwent CABG surgery.2
Reductions in the risk of death varied between angio-
graphic and clinical subgroups (Table 1) and were propor-
tional to the number of diseased coronary arteries and degree
of myocardial ischemia, particularly if disease of the left
anterior descending artery was present. Although relative
survival benefits were similar regardless of left ventricular
function (RR0.61 if normal, RR0.59 if abnormal), the
absolute benefit was greater among patients with an abnormal
ejection fraction because the risk of death with medical
therapy was twice as high in this group (5-year mortality,
25.2% versus 13.3%). Quantification of baseline risk with use
of a multivariable equation incorporating both clinical and
angiographic characteristics demonstrated that only patients
at moderate and high risk with medical therapy benefited
from CABG surgery, and those at low risk showed a trend
toward increased mortality with CABG surgery (Table 2).
Myocardial Infarction and Other Nonfatal
End Points
In these trials, the risk of subsequent myocardial infarction at
5 years was lower but not statistically significantly different
(24.4% in the CABG group versus 30.7% for the medical
group).2 Most trials did not prospectively collect data on
hospitalization for unstable angina, stroke, quality of life, or
cost.
Comments on First-Generation RCTs
Only 2649 patients were enrolled in these trials. Almost all
were men between 40 and 60 years of age. In current practice,
however, women and elderly patients commonly have CABG
surgery (most procedures are performed on patients 65
years old).1 Only 20% had an ejection fraction less than 50%.
Conducted 2 decades ago, these trials preceded numerous
improvements in both surgical and medical treatments. Only
3% were receiving antiplatelet drugs at enrollment, half the
patients were taking -adrenergic blockers, and HMG-CoA
reductase inhibitors were not available. Left internal thoracic
artery conduits were used in only 14% of patients in the
Coronary Artery Surgery Study.3
PTCA Versus Medical Therapy
The largest RCT of PTCA versus medical therapy enrolled
1018 relatively low-risk patients.4 Most had mild symptoms
(80% had Canadian Cardiovascular Society [CCS] class 0 to
II), with relatively low-risk CAD (93% with 1- or 2-vessel
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CAD, 94% with normal ventricular function). Death or
myocardial infarction occurred in 6.3% of PTCA patients and
3.3% of medical therapy patients (absolute difference, 3.0%;
95% confidence interval [CI], 0.4% to 5.7%; P0.02). The
combined rates of death, myocardial infarction, and nonpro-
tocol revascularization were 25% in both groups by 3 years
of follow-up, primarily because of repeat procedures in the
PTCA group for restenosis and for progression of symptoms
among the medical group. Patients with grade II or worse
angina had less angina and longer treadmill exercise times
after PTCA. Patients in the angioplasty group experienced
quicker improvement in quality-of-life measures, but by 3
years, no significant differences were present, partly because
27% of the medical group underwent angioplasty.5
The Atorvastatin Versus Revascularization Treatment
(AVERT) trial6 randomly assigned 341 patients with CCS
class 0 to II angina to receive either percutaneous coronary
intervention (PCI) plus “usual” medical care or to medical
care incorporating aggressive therapy with atorvastatin. Dur-
ing 18 months, the cumulative incidence of ischemic events
was greater after PCI (21% versus 13%, P0.048), but
differences were late, possibly related to progression of
disease. Greater improvements in anginal symptoms (54%
versus 41%, P0.009) occurred with PTCA.
These findings are reinforced by a systematic review7 of 6
prospective RCTs involving 1904 patients. Compared with
initial medical therapy, treatment with PTCA was associated
with a lower RR for angina (RR0.70; 95% CI, 0.50 to 0.98)
but a greater need for subsequent CABG (RR1.59; 95% CI,
1.09 to 2.32). Risks of death, myocardial infarction, or
subsequent PTCA were not significantly different (Figure 2).
Conclusions
Among low-risk patients with symptomatic CAD (CCS class
II or greater angina and average mortality 1% per year),
PTCA significantly improves symptoms and quality of life.
No impact is observed on subsequent procedures or myocar-
Figure 1. Overall survival after random allocation to medical
treatment or coronary artery bypass graft (CABG). At 5, 7, and
10 years, 10.2%, 15.8%, and 26.4% of patients, respectively,
assigned to CABG had died, compared with 15.8%, 21.7%, and
30.5% of their medically assigned counterparts. Risk reductions
(RR) were significant at all 3 time points (RR0.61, 0.68, 0.83).
Reprinted from Yusuf et al2 by permission of Elsevier Science
(The Lancet. 1994;344:563–570).
TABLE 1. Outcomes of Various Subgroups in Medical Therapy Versus CABG








P for CABG vs
Medical Treatment
Vessel disease
One vessel 271 9.9 0.54 (0.22–1.33) 0.18
Two vessels 859 11.7 0.84 (0.54–1.32) 0.45
Three vessels 1341 17.6 0.58 (0.42–0.80) 0.001
Left main artery 150 36.5 0.32 (0.15–0.70) 0.004
LAD disease present
One or 2 vessels 524 14.6 0.58 (0.34–1.01) 0.05
Three vessels 929 19.1 0.61 (0.42–0.88) 0.009
Left main artery 96 32.7 0.30 (0.11–0.84) 0.02
Overall 1549 18.3 0.58 (0.43–0.77) 0.001
LV function
Normal 2095 13.3 0.61 (0.46–0.81) 0.001
Abnormal 549 25.2 0.59 (0.39–0.91) 0.02
Exercise test status
Normal 585 11.6 0.78 (0.45–1.35) 0.38
Abnormal 1400 16.8 0.52 (0.37–0.72) 0.001
Severity of angina
Class 0, I, II 1716 12.5 0.63 (0.46–0.87) 0.005
Class III, IV 924 22.4 0.57 (0.40–0.81) 0.001
CABGcoronary artery bypass graft; CIconfidence interval; LADleft anterior descending;
LVleft ventricle.
Reprinted with permission from Elsevier Science (The Lancet. 1994;344:563–570).
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dial infarction, and the need for CABG increases. These data
suggest that PTCA is indicated if the desired level of anginal
relief and physical activity cannot be achieved with medical
therapy alone, but that prophylactic PTCA cannot be recom-
mended for the treatment of coronary artery stenosis in the
absence of angina or ischemia.
Recent Hybrid Trials
Several trials have compared medical treatment with revas-
cularization. The Asymptomatic Cardiac Ischemia Pilot
(ACIP) study prospectively assigned 558 patients who had
asymptomatic ischemia to 1 of 2 medication groups or routine
revascularization with CABG or PTCA. Despite the relatively
small sample size, after 2 years of follow-up, mortality was
significantly lower among patients assigned to routine revas-
cularization (1.1% versus 6.6% and 4.4% for the 2 medical
groups, P0.02), as were rates of death or myocardial
infarction (4.7% revascularization versus 12.1% and 8.8%,
P0.04).8 The Medicine, Angioplasty, or Surgery Study
(MASS)9 prospectively enrolled 214 patients who had prox-
imal left anterior descending artery stenoses to CABG sur-
gery with an internal thoracic arterial conduit, PTCA, or
medical therapy alone. After a mean follow-up of 3 years,
98% of CABG, 82% of PTCA, and 32% of medically treated
patients were asymptomatic. Rates of death or myocardial
infarction were low in all 3 groups (CABG group, 1%; PTCA
group, 2%; medical group, 1.4%). When subsequent proce-
dures were considered, the combined end point of death,
myocardial infarction, or repeat revascularization occurred in
3% of the CABG group, 24% of the PTCA group, and 17%
of the medical group.
A recently published Swiss study10 randomly assigned 305
elderly patients with severe angina (mean age, 80 years; 44%
women; 78% CCS III to IV angina despite a mean of 2.5
antianginal drugs) to immediate invasive or continued med-
ical strategies. Of patients assigned to an immediate invasive
approach, 52% received PTCA and 21% had CABG surgery;
22% continued medical treatment because they were unsuit-
able for any revascularization. Patients assigned to the inva-
sive strategy experienced more rapid improvement in mea-
sures of angina and quality of life (statistically significant
improvement at 6 months), but patients assigned to continued
medical therapy attained equivalent improvements by 12
months (partly because of a 48% delayed revascularization
rate). The proportion of patients who experienced death or
myocardial infarction by 1 year did not differ (17.0% invasive
versus 19.7% medical; hazard ratio, 0.90; 95% CI, 0.53 to
1.53; P0.71). Although small, this study supports the
important roles of both aggressive medical therapy and
selected revascularization procedures in improving symptoms
and quality of life in elderly patients.
Methodological Considerations for Comparison of
PTCA and CABG
Moderate- to High-Risk Patients
Several potential outcomes can be assessed: mortality, non-
fatal events, symptoms, costs, and surrogate laboratory end
points. Because PTCA and CABG have not been shown to
decrease nonfatal myocardial infarction in comparison with
medical therapy, the inclusion of nonfatal myocardial infarc-
tion in a composite end point could dilute statistical power
and preclude detection of a difference. Similarly, inclusion of
low-risk patients in whom CABG has not been shown to
improve survival, such as those with single-vessel disease,
would decrease the ability to detect mortality differences
between 2 modes of revascularization.
Because CABG surgery is associated with a 30% to 50%
mortality risk reduction in moderate- and high-risk subgroups
at 5 years compared with medical therapy, the detection or
exclusion of a risk difference of half this magnitude (15% to
25%) between CABG and PTCA would be clinically impor-
tant. If PTCA was superior to CABG, it could reasonably be
concluded that PTCA is superior to both medical therapy
(indirect extrapolation) and CABG (direct inference). How-
ever, if CABG surgery is superior to PTCA in terms of
survival, then PTCA could either be superior or inferior to
medical therapy. If enough data were available, the CI of any
observed difference between CABG surgery and PTCA could
be narrow enough (eg, 2010%) to make this inference.
If no difference were observed between CABG and PTCA,
it could be concluded that PTCA is equivalent to CABG only
if trials were large enough to reliably detect or exclude
relative differences in mortality of 20% (with narrow CIs)
Figure 2. Pooled risk ratios for various end points from 6 ran-
domized, controlled trials comparing percutaneous transluminal
coronary angioplasty (PTCA) with medical treatment in patients
with nonacute coronary heart disease (CABGcoronary artery
bypass grafting; n953 for PTCA and 951 for medical treat-
ment). Reproduced from Bucher et al7 by permission of British
Medical Journal.
TABLE 2. CABG Surgery Versus Medical Therapy: Subgroup









Low 783 6.3 1.17 (0.66–2.07) 0.60
Medium 784 13.9 0.55 (0.34–0.88) 0.01
High 783 25.2 0.54 (0.37–0.77) 0.001
*Tertiles of risk determined by a stepwise risk score incorporating both
clinical (age, angina, myocardial infarction, diabetes, hypertension) and angio-
graphic (ejection fraction, lesion location) variables.
Modified from Yusuf et al2 by permission of Elsevier Science (The Lancet.
1994;344:563–570).
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and included a large number of patients in whom CABG
improved prognosis. Approximately 600 deaths would be
needed in the “control” group to exclude an RR difference of
20% with 90% power; thus, trials with 8000 moderate- to
high-risk patients would be needed. Even with trials of this
magnitude, one could guarantee that only 40% to 50% of the
survival benefit of CABG surgery was preserved by PTCA
(by noninferiority analysis). To show that PTCA maintains at
least 50% of the demonstrated benefit of CABG on 5-year
mortality, the upper CI for the RR of a PTCA versus CABG
comparison should not exceed 1.15 (1-sided CI, 0.025).
To have 90% power to exclude differences smaller than this,
a sample size of 16 800 would be needed if 5-year CABG
mortality were 10% and 25 000 if it were 7%. If the
confidence limits of any difference included the possibility
that PTCA was worse than CABG by 50% (RR), it could not
be inferred that PTCA had a favorable effect on survival in
comparison with medical therapy.
Low-Risk Patients
Among low-risk patients (annual mortality 1%), assessing
mortality differences between PTCA and CABG could be
moot because CABG has not been shown to decrease mor-
tality. Approximately 16 000 patients would need to be
followed for 5 years to reliably detect a 20% risk difference
between the 2 modes of revascularization. With 4000
patients, only a very large RR difference between PTCA and
CABG surgery (eg, 50%) could be demonstrated. Available
data from individual trials or meta-analyses are insufficient to
exclude differences on the order of 20% because of small
sample sizes.
Among low-risk patients, therefore, the most relevant
comparison is between PTCA and medical therapy. Such
trials are unlikely to demonstrate a difference in mortality
between PTCA and medical therapy unless PTCA is harmful.
The inclusion of nonfatal myocardial infarction, overall rates
of which are unaffected by CABG or PTCA, into a composite
end point could dilute relative differences and decrease the
likelihood of detecting differences. Because both PTCA and
CABG are effective in relieving angina and myocardial
ischemia, a relevant composite end point could be death,
myocardial infarction, or severe angina (similar to the pri-
mary end point of the Trial of Invasive versus Medical
Therapy in Elderly Patients10).
Conclusions
These considerations indicate that to compare reliably the
relative effect of PTCA versus CABG and to avoid missing
clinically important differences, the following conditions
must be met: (1) inclusion of groups of patients in whom
surgery has been shown to be superior to medical therapy, (2)
inclusion of a sufficient number of patients, (3) follow-up of
at least 4 to 5 years to accrue a sufficient number of outcomes
and to obtain data well beyond the periprocedural period, and
(4) a high rate of compliance with the original treatment
allocation. If a substantial proportion of patients “cross over”
(30% to 40% by 5 years), the ability to detect differences in
survival is eroded substantially.
Trials of PTCA Versus CABG Surgery
Nine prospective RCTs with a total of 5200 patients have
compared balloon angioplasty with CABG surgery.9 The
largest trial was the Bypass Angioplasty Revascularization
Investigation (BARI).11 Five-year mortality among patients
assigned to CABG was 10.7% and 13.7% among those
assigned to PTCA (absolute difference, 3.0%; 95% CI,
0.2% to 6.0%; P0.19). Although the difference was not
statistically significant, power was less than 40% to detect the
observed risk difference. At 10 years of follow-up, mortality
was 26% after CABG versus 29.3% after PTCA (P0.12).12
The entire difference was confined to patients who had
treated diabetes mellitus (n353; 10-year mortality, 43.9%
CABG versus 55.9% PTCA; P0.012). No difference in
survival was noted among the rest of the patients (n1476;
10-year mortality, 21.8% CABG versus 23.2% PTCA;
P0.50). Importantly, only 15% of screened patients with
CAD were eligible for enrollment in BARI.11
A recent systematic review of available data demonstrated
a trend toward lower mortality with CABG (absolute risk
reduction [ARR], 1.1%; 95% CI, 0.1% to 2.3%; P0.08) at
3 years of follow-up and no difference in rates of nonfatal
myocardial infarction (ARR, 1.2%; 95% CI, 1.8% to 4.2%;
P0.42).13 Rates of repeat procedures were significantly
higher after PTCA (absolute risk increase, 34%; 95% CI,
28% to 42%; P0.001).13 Unfortunately, longer-term
follow-up is not available from all trials. Substudies have
demonstrated that PTCA and CABG produce similar benefits
on quality-of-life measures and are roughly equivalent in cost
over 3 to 5 years of follow-up.14,15
For patients with single-vessel disease, most of the data
come from the Randomised Intervention Treatment of An-
gina trial, which included 456 patients with single-vessel
disease.15 After a median 6.5 years of follow-up, no signifi-
cant difference in death or myocardial infarction was found
(16.7% CABG versus 19.3% PTCA), although repeat inter-
ventional procedures were required much more frequently
after PTCA (38% versus 12%, P0.01). These findings are
complemented by meta-analysis of data from patients with
single, proximal left anterior descending artery disease,13
which found no difference in occurrence of cardiac death or
myocardial infarction.
In summary, 5200 patients with CAD have been enrolled in
9 trials of PTCA (balloon angioplasty) versus CABG surgery.
No trial individually had sufficient power to detect or exclude
differences in mortality, and various composite clinical end
points were used. The main findings are that, in the popula-
tions studied, cumulative mortality and death or myocardial
infarction rates were no different and that repeat procedures
are required more frequently after PTCA. The low proportion
of screened patients eligible for enrollment raises questions
about generalizability of the results. Restenosis is a major
limitation of PTCA, but initial morbidity is less and anginal
relief nearly equivalent by 3 years.
Methodological Considerations
Are PTCA and CABG equivalent modes of revascularization
for multivessel disease among angiographically eligible pa-
tients, except for restenosis? To answer this question, the
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marked heterogeneity of what is termed “multivessel disease”
must be considered. A patient with discrete lesions of the
right coronary and circumflex arteries who has a normal left
ventricle or a patient with diffuse 3-vessel disease and an
ejection fraction of 30% can rightly be classified as having
multivessel disease; yet, the inherent prognoses and the
potential risks and benefits of revascularization vary consid-
erably. In the PTCA versus CABG trials, relatively low-risk
patients were enrolled; fewer than 20% had left ventricular
dysfunction and almost 70% had 1- or 2-vessel disease. In a
meta-analysis of 8 trials,16 the observed first-year mortality of
2.6% and 1.1% per year thereafter confirms the relatively
low-risk status of these patients. Although patients enrolled in
BARI had higher observed mortality rates, even in this trial,
nearly 60% of patients had 2-vessel CAD, whereas 60% of
patients enrolled in the earlier CABG versus medical therapy
trials had 3-vessel or left main CAD.2 Therefore, the trials
comparing the 2 modes of revascularization include a signif-
icant proportion of patients in whom CABG has not been
shown to be superior to medical therapy, and the total
enrollment of 5200 patients yields low power to demonstrate
differences in mortality on the order of 20% to 30%. The 95%
CIs suggest the absolute risk of mortality after CABG surgery
could be lower by 2.3% (23 fewer deaths per 1000 patients
treated by 3 years) or higher by 0.1% (1 more death per 1000
patients treated by 3 years).13
Relative Impact of PTCA and CABG Surgery
Among Patients With Diabetes Mellitus
Among patients with diabetes mellitus in the BARI random-
ized trial, the estimated 7-year mortality was 23.6% after
CABG and 44.3% after PTCA, a difference equating to 200
lives per 1000 patients treated (P0.0011).17 This difference
was confined to diabetic patients who received at least 1
internal thoracic artery graft (7-year survival, 83.2%,
n140), whereas those who received only saphenous vein
grafts had a 7-year survival (54.5%, n33), similar to those
who had PTCA (55.5%, n170). Interestingly, the risk of
subsequent myocardial infarction did not differ between
groups.17,18 When available data from the Emory Angioplasty
versus Surgery Trial and the Coronary Angioplasty versus
Bypass Revascularization Investigation are included, an ad-
vantage in favor of CABG is apparent at 4 years (ARR, 8.6%;
95% CI, 2.2% to 15%; P0.01) but not at 6.5 years (ARR,
3.9%; 95% CI, 17% to 25%; P0.71).13
This observation has generated intense interest and debate.
The key methodological question is whether the observed
outcomes among diabetic patients in BARI are real or simply
the result of chance. These findings must be interpreted
carefully because analyses of subgroups can overestimate or
even mislead the direction of treatment effect,19 and overall
trial results could be a better indicator of treatment effect than
the apparent effect within a subgroup. The observations of the
BARI trial have not been reproduced consistently in other
large trials or observational datasets, including the BARI
registry, with physician-selected revascularization.20 In both
trials and observational datasets, however, diabetes mellitus
is clearly a marker for higher risk, and prognosis is worse
after either PTCA or CABG surgery.11 One resolution to the
apparent dilemma could be that higher-risk patients derive a
mortality benefit from CABG surgery, and longer-term out-
comes of both procedures are equivalent in lower-risk
patients.
Impact of Stents on Outcomes
After Revascularization
Initially used for treatment of coronary artery dissections
after angioplasty, stents are now used widely in many patient
subsets, frequently as an alternative to medical therapy or
CABG surgery. Twenty-five RCTs studied the effects of
stents versus balloon angioplasty on the clinical outcomes of
death, death or myocardial infarction, and repeat procedures
in patients with chronic CAD. The results have been analyzed
systematically by the National Institute of Clinical Excellence
of the National Health Service of the UK.21 Although
unblinded, with crossovers allowed and with no single
definitive study, consistency of results across trials was
observed. In the aggregate, no significant differences were
observed in overall mortality at 4 to 11 months of follow-up
(0.85% stent versus 1.3% PTCA; odds ratio [OR], 0.68; 95%
CI, 0.40 to 1.14) or myocardial infarction (4.4% stent versus
3.6% PTCA; OR, 1.23; 95% CI, 0.86 to 1.72). The odds of
revascularization procedures were nearly 50% lower with
stenting (12.4% versus 20.6%; OR, 0.54; 95% CI, 0.45 to
0.65).
Several prospective RCTs have compared stenting with
CABG surgery. Meta-analysis of data from 3 RCTs with a
total enrollment of 2643 patients13 indicates no significant
differences in mortality (ARR in favor of stenting, 0.82; 95%
CI, 4.3 to 5.9; P0.75) or nonfatal myocardial infarction
(ARR in favor of stenting, 2.9%; 95% CI, 0.6% to 5.1%;
P0.01) at 3 years. The 1-year 15% repeat revascularization
rate observed after stenting is approximately half the corre-
sponding 1-year repeat revascularization rate after balloon
angioplasty and is consistent with the findings of the stent
versus balloon trials described previously.16 The need for
repeat procedures remains significantly higher after stenting
compared with CABG surgery (ARR in favor of CABG,
15%; 95% CI, 10% to 20%; P0.001).
Of the 1205 enrollees in the Arterial Revascularization
Therapy Study trial, 208 (17%) were diabetic.22 Diabetic
patients experienced higher rates of death, myocardial infarc-
tion, and repeat revascularization at 1 year (39.3% after
stenting versus 17.7% after CABG; absolute difference,
21.6%; P0.001), largely because of a much lower need for
repeat revascularization after CABG (3.1% versus 22.3%,
P0.001). Diabetes was an independent predictor of adverse
events at 1 year (RR, 2.07). More data and longer-term
follow-up are needed.
Early data indicate that new developments in stent tech-
nology such as local drug elution further reduce the need for
repeat procedures but do not influence rates of death or
myocardial infarction.23
Database Studies
To minimize biases, we have focused on available data from
prospective RCTs. Data from large prospective databases,
although subject to referral and selection biases, in general
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support the framework of a risk-based approach to revascu-
larization. For example, long-term survival with 97%
follow-up for 9263 patients with CAD has been reported by
the Duke Registry.24 Over a spectrum of baseline risk, CABG
was associated with improved long-term outcomes in com-
parison with medical therapy among patients in moderate-
and high-risk strata, and PTCA was superior to medical
therapy only among low-risk strata.24 Compared with PTCA,
CABG was associated with improved outcomes among high-
risk strata (chiefly those with involvement of the proximal
left anterior descending artery), and PTCA was superior to
CABG among low-risk patients. Problems unique to obser-
vational studies such as determination of time zero and
assignment of deaths occurring while awaiting revasculariza-
tion point to the need for larger prospective RCTs of
up-to-date therapies.
Methodological Limitations of Available Data
Invasive or surgical trials are complex, tend to be small
compared with drug therapy trials, and are inherently open
label. Such trials usually compare 2 active treatments, thereby
decreasing the chances of detecting differences among arms
(unless 1 procedure is harmful). Crossover to the other
therapy further decreases the ability to detect differences and
occurs with increasing frequency during the course of follow-
up, necessitating consideration of therapeutic strategies rather
than specific treatments. The most important limitation of the
currently available data is the low statistical power to detect
plausible differences in clinical outcomes, particularly death.
This low statistical power is attributable to both the relatively
low numbers of events (low-risk populations studied) and the
relatively low numbers of patients recruited. Systematic
reviews, preferably based on individual patient data and
extended follow-up, can provide some redress. Generalizabil-
ity of trial results has also been questioned, because a
minority of screened patients are generally eligible, only
some of whom ultimately consent and are enrolled into
trials.25 Larger, definitive trials comparing current medical,
interventional, and surgical therapies, particularly in patients
at moderate to high risk of events, are urgently needed.
Summary of Considerations for Myocardial
Revascularization for Chronic Stable Angina
Based on Currently Available Evidence
CABG Surgery Versus Medical Therapy
1. Mortality benefits of CABG surgery are proportional to
baseline patient risk.
2. CABG surgery does not reduce the overall incidence of
nonfatal myocardial infarction.
3. CABG is effective for symptom improvement.
Balloon Angioplasty Versus Medical Therapy
1. Balloon angioplasty is indicated for symptom improve-
ment but not merely for the presence of an anatomic
stenosis.
2. Balloon angioplasty does not prevent death or myocardial
infarction.
3. Balloon angioplasty is associated with a greater need for
subsequent CABG surgery.
Stents Versus Balloon Angioplasty
1. Stents are indicated for the treatment of arterial dissections
with abrupt or threatened vessel closure after balloon
angioplasty.
2. Stents decrease rates of angiographic restenosis repeat
procedures but not those of death or myocardial infarction.
PCI Versus CABG
1. CABG surgery is likely preferred for high-risk patients
such as those with left main, severe 3-vessel, or diffuse
disease, severe ventricular dysfunction, or diabetes
mellitus.
2. Both PCI and CABG provide good symptom relief.
3. Repeat procedures are required more frequently after PCI.
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